DaVita HealthCare Partners Inc (DVA)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NYSE
Market Cap: $10.98B
Last updated: Nov 17, 2026 at 11:04 AM ET
DaVita HealthCare Partners Inc (DVA) Stock Forecast
Analysts expect DaVita HealthCare Partners (DVA) to earn $14.70 per share in the fiscal year ending Dec 31, 2026, on revenue of $14.25B. Of 8 analysts, 3 rate the stock Buy or Strong Buy, 4 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 2.88, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 38% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 3 | 37.5% |
| Hold | 4 | 50.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 12.5% |
- Consensus
- Hold
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 14.8% and revenue estimates rise 3.5%.
- Fiscal year ending Dec 31, 2026
- $14.70
- EPS consensus, revenue $14.25B
- Fiscal year ending Dec 31, 2027
- $16.88
- EPS consensus, revenue $14.75B
- Next report
- Feb 1, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $14.70 | $14.34 to $14.98 | 6 | $14.25B | $14.18B to $14.50B | 6 |
| Dec 31, 2027 | $16.88 | $16.33 to $18.41 | 8 | $14.75B | $14.51B to $15.28B | 7 |
Quarterly Estimates
The EPS consensus falls from $4.19 for the quarter ending Dec 31, 2026 to $3.30 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $4.19 | $3.92 to $4.56 | 8 | $3.69B | $3.56B to $3.86B | 7 |
| Mar 31, 2027 | $3.30 | $3.15 to $3.53 | 3 | $3.52B | $3.51B to $3.54B | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 9 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 3 |
| Fiscal year ending Dec 31, 2027 | 0 | 5 |
| Quarter ending Mar 31, 2027 | 1 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 1.0% from $14.85.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $14.70 | $14.70 | $14.82 | $14.85 | $14.85 | -1.0% |
| Fiscal year ending Dec 31, 2027 | $16.88 | $16.87 | $17.14 | $17.25 | $17.02 | -0.8% |
| Quarter ending Mar 31, 2027 | $3.30 | $3.30 | $3.31 | $3.33 | $3.26 | +1.3% |
Frequently Asked Questions About DVA
What is the DVA stock forecast?
Consensus analyst estimates put DaVita HealthCare Partners's EPS at $14.70 for the fiscal year ending Dec 31, 2026, on revenue of $14.25B. The consensus rating from 8 analysts is Hold.
How do analysts rate DVA stock?
Of 8 analysts covering DaVita HealthCare Partners, 0 rate it Strong Buy, 3 Buy, 4 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from DVA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $14.70, with estimates from $14.34 to $14.98 from 6 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $16.88, with estimates from $16.33 to $18.41 from 8 analysts.
What revenue do analysts expect from DaVita HealthCare Partners next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $14.25B, with estimates from $14.18B to $14.50B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $14.75B, with estimates from $14.51B to $15.28B.
How many analysts cover DVA?
8 analysts rate DaVita HealthCare Partners stock, and 6 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
DVA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors